uniQure
QURE
Performance
About uniQure
uniQure is a global biopharmaceutical company focused on developing gene therapies for serious genetic diseases, with a translational pipeline and manufacturing capabilities. The company emphasizes genomic medicine and innovative cures, particularly in neurodegenerative diseases such as Huntington’s disease, and maintains operations in Europe and the United States. Their work spans research programs, clinical trials, and partnerships to advance adeno-associated virus (AAV) platform therapies. uniQure positions itself as a leader in the field of gene therapy, driving science innovation and patient-focused initiatives.
Recent News
UniQure Pauses Higher Doses in Fabry Study; Aro Shares Pompe Data
World Hemophilia Day 2026: New Treatment Era and Improving Diagnosis
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Deep Dive: Huntington’s at a Crossroads
FDA Bolsters Bespoke Therapy Framework with New Draft Safety Guidelines
Seven Biotech Companies to Know in the Netherlands
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
FDA, After Turbulent Year, Leaves Drugmakers Guessing on Its Direction
STAT+: A Huntington’s Researcher on the UniQure-FDA Fray
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
Rare Disease Advocacy Group Urges Trump Administration to Restore FDA Clarity
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
Recent Deals
No recent deals for this company.
